Kristoffer Nordstrom - Xvivo Perfusion CFO Relations
| XVIPF Stock | USD 41.23 0.77 1.83% |
Insider
Kristoffer Nordstrom is CFO Relations of Xvivo Perfusion AB
| Age | 38 |
| Phone | 46 3 17 88 21 50 |
| Web | https://www.xvivoperfusion.com |
Xvivo Perfusion Management Efficiency
Xvivo Perfusion's management efficiency ratios could be used to measure how well Xvivo Perfusion manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Denice Torres | Glaukos Corp | 60 | |
| Salvador Dada | Establishment Labs Holdings | 42 | |
| Moshe Mizrahy | InMode | 71 | |
| Tomas Navratil | Glaukos Corp | ||
| Michael Kreindel | InMode | 56 | |
| Dena Truelove | Inari Medical | N/A | |
| John Carey | TransMedics Group | 59 | |
| Jared Oasheim | CVRx Inc | 40 | |
| Diane Biagianti | Glaukos Corp | 64 | |
| Ed Joyce | Axogen Inc | N/A | |
| Gregory Davault | Axogen Inc | 56 | |
| Heather Brennan | Establishment Labs Holdings | N/A | |
| Mory Gharib | Glaukos Corp | N/A | |
| Bradley JD | Axogen Inc | 54 | |
| Thomas MD | Inari Medical | 51 | |
| Nava TalLauner | InMode | ||
| Jeffrey Bettinger | Establishment Labs Holdings | N/A | |
| Alex Shvartsburg | LivaNova PLC | 54 | |
| Andrew Hykes | Inari Medical | 51 | |
| Lauren Budden | Insulet | 49 | |
| Rajbir Denhoy | Establishment Labs Holdings | 53 | |
Management Performance
| Return On Equity | 0.0136 | |||
| Return On Asset | 0.0057 |
Xvivo Perfusion AB Leadership Team
Elected by the shareholders, the Xvivo Perfusion's board of directors comprises two types of representatives: Xvivo Perfusion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xvivo. The board's role is to monitor Xvivo Perfusion's management team and ensure that shareholders' interests are well served. Xvivo Perfusion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xvivo Perfusion's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jaya Tiwari, VP Affairs | ||
| Magnus Nilsson, Advisor | ||
| Katrin Gisselfalt, Global Director | ||
| Charlotte Walldal, Global director | ||
| Lena BSc, Chief Officer | ||
| Andreas MD, Chief Officer | ||
| Johan Holmstrom, Chief Officer | ||
| Christoffer Rosenblad, Deputy CEO, CFO | ||
| Christer Flon, Mang | ||
| Kristoffer Nordstrom, CFO Relations |
Xvivo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Xvivo Perfusion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0136 | |||
| Return On Asset | 0.0057 | |||
| Profit Margin | 0.04 % | |||
| Current Valuation | 536.1 M | |||
| Shares Outstanding | 29.83 M | |||
| Shares Owned By Insiders | 12.25 % | |||
| Shares Owned By Institutions | 54.00 % | |||
| Price To Earning | 166.11 X | |||
| Price To Book | 4.58 X | |||
| Price To Sales | 16.90 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Xvivo Pink Sheet
Xvivo Perfusion financial ratios help investors to determine whether Xvivo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xvivo with respect to the benefits of owning Xvivo Perfusion security.